CAPTRUST Financial Advisors
CGTX icon

CAPTRUST Financial Advisors’s Cognition Therapeutics CGTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10K Buy
+10,377
New +$10.4K ﹤0.01% 3352
2022
Q4 		– Sell
-50,000
Closed -$95K – 2081
2022
Q3 		$95K Buy
+50,000
New +$104K ﹤0.01% 1939

Other funds holding CGTX

Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Hilton Capital Management
Hilton Capital Management Garden City, New York $1.47B AUM 11.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
American Financial Group
American Financial Group Cincinnati, Ohio $286M AUM 0.58% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
McAdam LLC
McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

CAPTRUST Financial Advisors's CGTX Position: Q3 2026 in Review

CAPTRUST Financial Advisors opened a new position in Cognition Therapeutics (CGTX) in Q3 2026: 10,377 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #3352 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in CGTX as recently as Q3 2022.

CAPTRUST Financial Advisors first reported a position in CGTX in Q3 2022 and has held it in 2 quarters since. The position peaked at $95K in Q3 2022. 41 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • CAPTRUST Financial Advisors held 10,377 shares of Cognition Therapeutics worth $10K as of Q3 2026.
  • Cognition Therapeutics was a new CAPTRUST Financial Advisors position in Q3 2026.
  • Cognition Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3352 holding.
  • CAPTRUST Financial Advisors first reported a position in Cognition Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • CAPTRUST Financial Advisors's Cognition Therapeutics position peaked at $95K in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.